Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

This study is ongoing, but not recruiting participants.

Study NCT00061945 Information provided by Cancer and Leukemia Group B

First Received: June 5, 2003 Last Updated: April 20, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	May 2017
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Publications:

Stock W, Sanford B, Lozanski G, et al.: Alemtuzumab can be incorporated Into front-line therapy of adult acute lymphoblastic leukemia (ALL): final pase I results of a Cancer and Leukemia Group B study (CALGB 10102). [Abstract] Blood 114 (22): A-838, 2009.

Lozanski G, Sanford B, Mrozek K, et al.: Quantitative measurement of CD52 expression and alemtuzumab binding in adult acute lymphoblastic leukemia (ALL): correlation with immunophenotype and cytogenetics in patients (pts) enrolled on a phase I/II trial from the Cancer and Leukemia Group B (CALGB 10102). [Abstract] Blood 110 (11): A-2386, 2007.

Stock W, Yu D, Sanford B, et al.: Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia (ALL) is feasible: a phase I/II study from the Cancer and Leukemia Group B (CALGB 10102). [Abstract] Blood 106 (11): A-145, 2005.